Chengda Biotech Invests 1 Billion Yuan to Establish AI Pharmaceutical Tech Company in Shanghai

Vaccine Leader Crosses Into AI With 1 Billion Yuan Investment in Shanghai

According to 36Kr, business registration platform Aiqicha shows that Shanghai Chengda Zhiyuan Pharmaceutical Technology Co., Ltd. was recently officially established. The company's legal representative is Li Yeji, with a registered capital of 1 billion yuan (approximately $137 million). It is wholly owned by Liaoning Chengda Biotech Co., Ltd. This move signifies that Chengda Biotech, a well-known domestic vaccine company, is formally extending its reach into the intersection of artificial intelligence and pharmaceutical technology.

Business Scope Focuses on Full-Chain AI Capability Building

According to business registration information, Shanghai Chengda Zhiyuan Pharmaceutical Technology's scope of operations is notably extensive, covering AI theory and algorithm software development, AI foundational software development, AI application software development, and AI innovation and entrepreneurship service platforms, among other business areas. This layout not only spans the complete AI technology chain from underlying algorithms to upper-layer applications but also involves building platform-based service capabilities, indicating that Chengda Biotech's strategic ambitions in AI go far beyond simple technology adoption or tool application.

Notably, the company name includes the term "pharmaceutical technology," suggesting that its AI capability building will be closely centered on the core pharmaceutical and health business rather than positioning itself as a pure technology company.

AI + Biopharmaceutical Sector Continues to Heat Up

Chengda Biotech's move is far from an isolated case. In recent years, AI-driven drug discovery (AI for Drug Discovery) has become one of the hottest areas in the global biopharmaceutical field. From target identification and molecular design to clinical trial optimization, artificial intelligence is reshaping every stage of new drug development.

Domestically, AI pharmaceutical companies such as XtalPi and Insilico Medicine have successively secured large-scale financing or even successfully gone public. Meanwhile, traditional pharmaceutical companies are also accelerating their embrace of AI technology:

• Hengrui Medicine has previously partnered with multiple AI companies to explore AI-assisted drug development;
• WuXi AppTec continues to increase investment in computational chemistry and AI platform construction;
• Several vaccine companies are also exploring the use of AI to optimize antigen design and production processes.

As the leading domestic enterprise in the human rabies vaccine segment, Chengda Biotech's decision to enter the AI sector through a wholly-owned subsidiary with a substantial 1 billion yuan investment reflects its firm conviction in the convergence trend of AI and biopharmaceuticals.

Choosing Shanghai: Dual Considerations of Talent and Ecosystem

The choice to locate the new company in Shanghai is equally noteworthy. Shanghai is not only a core hub for China's biopharmaceutical industry, home to mature industrial clusters such as Zhangjiang Pharma Valley, but also one of the cities with the highest concentration of AI talent. In recent years, the Shanghai municipal government has continuously introduced policies supporting the integrated development of AI and biopharmaceuticals, providing companies with a favorable policy environment and industrial infrastructure. By establishing the new company in Shanghai, Chengda Biotech can access top-tier AI and pharmaceutical interdisciplinary talent and integrate into the city's mature innovation ecosystem.

Outlook: The AI Transformation Journey of Traditional Pharma

Although the 1 billion yuan registered capital demonstrates Chengda Biotech's determination, the path from traditional biopharmaceutical enterprise to AI transformation is by no means smooth. Building a technical team, constructing data infrastructure, and deeply integrating R&D pipelines with AI capabilities will all be real challenges facing Chengda Zhiyuan.

However, from an industry perspective, the deep integration of AI and biopharmaceuticals is an irreversible trend. Chengda Biotech's proactive move to lay the groundwork for foundational AI capabilities positions it to gain a competitive edge in the future. The company's subsequent actions regarding specific product directions, technology roadmaps, and talent recruitment deserve continued attention from the industry.